Fajun Xie
Overview
Explore the profile of Fajun Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wang F, Qin J, Xie F, Wu Q, Lu H
Lung Cancer
. 2020 Jan;
140:118-120.
PMID: 31924369
No abstract available.
12.
Xu Y, Huang Z, Lu H, Yu X, Li Y, Li W, et al.
Br J Cancer
. 2019 Sep;
121(8):640-646.
PMID: 31523058
Background: Small-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth...
13.
Gong L, Qin J, Xie F, Han N, Lu H
J Thorac Oncol
. 2019 May;
14(6):e120-e123.
PMID: 31122562
No abstract available.
14.
Lu H, Qin J, Han N, Xie F, Gong L, Li C
Integr Cancer Ther
. 2018 Sep;
17(4):1109-1114.
PMID: 30229683
Background: Irinotecan (CPT-11) can be used as a first-line therapeutic drug against extensive-stage small cell lung cancer (SCLC); it can also be used in second-line treatment for SCLC. CPT-11-induced delayed...
15.
Lu H, Xie F, Huang Z, Qin J, Han N, Mao W
Adv Clin Exp Med
. 2018 Jul;
27(9):1195-1199.
PMID: 30016011
Background: The prognosis for small-cell lung cancer (SCLC) is very poor, so a new therapeutic strategy and new drugs are imperative. Objectives: The aim of this study was to examine...
16.
Lu H, Qin J, Han N, Lei L, Xie F, Li C
Onco Targets Ther
. 2018 May;
11:2217-2226.
PMID: 29720878
Background: Small cell lung cancer (SCLC) is an aggressive and deadly neuroendocrine tumor derived from bronchial epithelial cells. Although it results in a 95% mortality rate, the development of targeted...
17.
Lu H, Chen B, Qin J, Xie F, Han N, Huang Z
Oncol Lett
. 2018 Mar;
15(4):5799-5802.
PMID: 29552210
The present study describes the case of a 48-year-old man who was diagnosed with lung adenocarcinoma with an epidermal growth factor receptor (EGFR) 21 L858R mutation. The patient received surgery...
18.
Lu H, Yang S, Zhu H, Tong X, Xie F, Qin J, et al.
BMC Cancer
. 2018 Mar;
18(1):251.
PMID: 29506494
Background: Esophageal sarcomatoid carcinoma (ESC) is a rare disease with a mixture of both carcinomatous and sarcomatous components in the tumor. Its genetic background and mechanisms of oncogenesis remain largely...
19.
Lu H, Qin J, Xu H, Han N, Xie F, Mao W
Exp Ther Med
. 2017 Jul;
14(1):398-402.
PMID: 28672945
Small cell lung cancer (SCLC) is sensitive to first-line chemotherapy and radiotherapy, but frequently recurs. Temozolomide is a chemotherapeutic drug suitable for the treatment of relapsed SCLC, particularly when brain...
20.
Fan Y, Xu Y, Gong L, Fang L, Lu H, Qin J, et al.
Sci Rep
. 2017 Mar;
7:45193.
PMID: 28332624
EGFR-TKIs and radiation therapy (RT) are the principal treatment for patients with brain metastases (BM) and EGFR mutant NSCLC. However, the optimal use of brain RT for patients with asymptomatic...